845 related articles for article (PubMed ID: 28965047)
1. Physicochemical stability and aerosolization performance of dry powder inhalation system containing ciprofloxacin hydrochloride.
Karimi K; Katona G; Csóka I; Ambrus R
J Pharm Biomed Anal; 2018 Jan; 148():73-79. PubMed ID: 28965047
[TBL] [Abstract][Full Text] [Related]
2. L-Leucine as an excipient against moisture on in vitro aerosolization performances of highly hygroscopic spray-dried powders.
Li L; Sun S; Parumasivam T; Denman JA; Gengenbach T; Tang P; Mao S; Chan HK
Eur J Pharm Biopharm; 2016 May; 102():132-41. PubMed ID: 26970252
[TBL] [Abstract][Full Text] [Related]
3. Protection of hydrophobic amino acids against moisture-induced deterioration in the aerosolization performance of highly hygroscopic spray-dried powders.
Yu J; Chan HK; Gengenbach T; Denman JA
Eur J Pharm Biopharm; 2017 Oct; 119():224-234. PubMed ID: 28655664
[TBL] [Abstract][Full Text] [Related]
4. The influence of storage relative humidity on aerosolization of co-spray dried powders of hygroscopic kanamycin with the hydrophobic drug rifampicin.
Momin MAM; Tucker IG; Das SC
Drug Dev Ind Pharm; 2019 Jul; 45(7):1205-1213. PubMed ID: 30990097
[TBL] [Abstract][Full Text] [Related]
5. Influence of excipients on physical and aerosolization stability of spray dried high-dose powder formulations for inhalation.
Shetty N; Park H; Zemlyanov D; Mangal S; Bhujbal S; Zhou QT
Int J Pharm; 2018 Jun; 544(1):222-234. PubMed ID: 29678544
[TBL] [Abstract][Full Text] [Related]
6. Improved Physical Stability and Aerosolization of Inhalable Amorphous Ciprofloxacin Powder Formulations by Incorporating Synergistic Colistin.
Shetty N; Ahn P; Park H; Bhujbal S; Zemlyanov D; Cavallaro A; Mangal S; Li J; Zhou QT
Mol Pharm; 2018 Sep; 15(9):4004-4020. PubMed ID: 30028947
[TBL] [Abstract][Full Text] [Related]
7. Development of a microparticle-based dry powder inhalation formulation of ciprofloxacin hydrochloride applying the quality by design approach.
Karimi K; Pallagi E; Szabó-Révész P; Csóka I; Ambrus R
Drug Des Devel Ther; 2016; 10():3331-3343. PubMed ID: 27784991
[TBL] [Abstract][Full Text] [Related]
8. Heat-Stable Dry Powder Oxytocin Formulations for Delivery by Oral Inhalation.
Fabio K; Curley K; Guarneri J; Adamo B; Laurenzi B; Grant M; Offord R; Kraft K; Leone-Bay A
AAPS PharmSciTech; 2015 Dec; 16(6):1299-306. PubMed ID: 25776985
[TBL] [Abstract][Full Text] [Related]
9. Development of a novel dry powder inhalation formulation for the delivery of rivastigmine hydrogen tartrate.
Simon A; Amaro MI; Cabral LM; Healy AM; de Sousa VP
Int J Pharm; 2016 Mar; 501(1-2):124-38. PubMed ID: 26836711
[TBL] [Abstract][Full Text] [Related]
10. Development and characterization of a spray-dried inhalable ciprofloxacin-quercetin co-amorphous system.
Alhajj N; O'Reilly NJ; Cathcart H
Int J Pharm; 2022 Apr; 618():121657. PubMed ID: 35288220
[TBL] [Abstract][Full Text] [Related]
11. Co-spray dried carbohydrate microparticles: crystallisation delay/inhibition and improved aerosolization characteristics through the incorporation of hydroxypropyl-β-cyclodextrin with amorphous raffinose or trehalose.
Amaro MI; Tajber L; Corrigan OI; Healy AM
Pharm Res; 2015 Jan; 32(1):180-95. PubMed ID: 25074469
[TBL] [Abstract][Full Text] [Related]
12. D-leucine microparticles as an excipient to improve the aerosolization performances of dry powders for inhalation.
Schoubben A; Vivani R; Paolantoni M; Perinelli DR; Gioiello A; Macchiarulo A; Ricci M
Eur J Pharm Sci; 2019 Mar; 130():54-64. PubMed ID: 30677523
[TBL] [Abstract][Full Text] [Related]
13. Nano spray-dried pyrazinamide-L-leucine dry powders, physical properties and feasibility used as dry powder aerosols.
Kaewjan K; Srichana T
Pharm Dev Technol; 2016; 21(1):68-75. PubMed ID: 25331092
[TBL] [Abstract][Full Text] [Related]
14. Dry powders for the inhalation of ciprofloxacin or levofloxacin combined with a mucolytic agent for cystic fibrosis patients.
Akdag Cayli Y; Sahin S; Buttini F; Balducci AG; Montanari S; Vural I; Oner L
Drug Dev Ind Pharm; 2017 Aug; 43(8):1378-1389. PubMed ID: 28420285
[TBL] [Abstract][Full Text] [Related]
15. Optimization of Ciprofloxacin Hydrochloride Spray-Dried Microparticles for Pulmonary Delivery Using Design of Experiments.
Razuc M; Piña J; Ramírez-Rigo MV
AAPS PharmSciTech; 2018 Oct; 19(7):3085-3096. PubMed ID: 30105497
[TBL] [Abstract][Full Text] [Related]
16. Overcoming dose limitations using the orbital(®) multi-breath dry powder inhaler.
Young PM; Crapper J; Philips G; Sharma K; Chan HK; Traini D
J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):138-47. PubMed ID: 24004178
[TBL] [Abstract][Full Text] [Related]
17. Design, characterization, and aerosol dispersion performance modeling of advanced co-spray dried antibiotics with mannitol as respirable microparticles/nanoparticles for targeted pulmonary delivery as dry powder inhalers.
Li X; Vogt FG; Hayes D; Mansour HM
J Pharm Sci; 2014 Sep; 103(9):2937-2949. PubMed ID: 24740732
[TBL] [Abstract][Full Text] [Related]
18. Dry powder inhalers of gentamicin and leucine: formulation parameters, aerosol performance and in vitro toxicity on CuFi1 cells.
Aquino RP; Prota L; Auriemma G; Santoro A; Mencherini T; Colombo G; Russo P
Int J Pharm; 2012 Apr; 426(1-2):100-107. PubMed ID: 22301426
[TBL] [Abstract][Full Text] [Related]
19. Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections.
Lin Y; Chang RYK; Britton WJ; Morales S; Kutter E; Li J; Chan HK
Eur J Pharm Biopharm; 2019 Sep; 142():543-552. PubMed ID: 31398437
[TBL] [Abstract][Full Text] [Related]
20. Powder, capsule and device: An imperative ménage à trois for respirable dry powders.
Schoubben A; Blasi P; Giontella A; Giovagnoli S; Ricci M
Int J Pharm; 2015 Oct; 494(1):40-8. PubMed ID: 26255220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
